Drs. Manish Shah and Sarah Rutherford explore the groundbreaking research presented at the 2025 ASCO Annual Meeting. They discuss key developments from this year’s meeting, including new immunotherapy and targeted therapy options, the use of circulating tumor cell (ctDNA) and minimal residual disease (MRD) testing, the importance of selecting the right patients for the right treatments, and more. They also provide insights into how personalized and precision treatment options have the potential to reshape cancer care and minimize patients’ side effects.

The American Society of Clinical Oncology, or ASCO, Annual Meeting is the largest oncology conference. Each year, the meeting brings together oncology experts, thought leaders and professionals from around the world to share cancer care insights and present state-of-the-art research poised to impact patient care.

Guest: Sarah Rutherford, MD, a hematologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.